Toggle menu

TICH 2 Trial

Start date:
October 2013
End date:
February 2018
Co-ordinated by:
University of Nottingham
Main trial site:
http://tich-2.org

Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage

Aim

To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.

Trial Design

A phase III prospective pragmatic double blind randomised placebo controlled trial

Chief Investigator

Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham

Principal Investigator

Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian

Local lead in ED

Dr Matt Reed is the local contact for recruitment of ED patients into the study.

Research Team

  • EMERGE Research team
  • Stroke Research Group

Eligibility criteria (summary)

Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.

Further information

For more information please refer to main trial website

Research Team

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Bernadette Gallagher

Senior Research Nurse

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)

Molecular and cellular analysis of intracranial tumours

Read more

BRAINED Study

Molecular and cellular analysis of intracranial tumours